Dianthus Therapeutics, Inc. /DE/ Restructuring Charges
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Restructuring Charges of $1.92 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2023-08-03
- Dianthus Therapeutics, Inc. /DE/ restructuring charges for the quarter ending 2023-06-30 was $1.92M.
- Dianthus Therapeutics, Inc. /DE/ restructuring charges for the quarter ending 2023-03-31 was $18.00M.
- Dianthus Therapeutics, Inc. /DE/ restructuring charges for the quarter ending 2022-06-30 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ restructuring charges for the quarter ending 2022-03-31 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month |
|---|---|---|
| 2023-06-30 | $1.92M 10-Q · filed 2023-08-03 | $19.92M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $18.00M 10-Q · filed 2023-05-15 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |